CEL-SCI Corp. reported that Aintree University Hospital, in Liverpool, England, has become a clinical site for the Company's global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine (Leukocyte Interleukin, Injection).
This is the first center to join the Multikine Phase III study in the UK.
Aintree University Hospital is a large teaching hospital in Liverpool providing a range of acute and non-acute specialties. The hospital offers specialist services to a population of 1.5 million residents across the Northwest of England.
In a release, the Company noted that the Principal Investigator for the trial site is Professor Richard Shaw. He serves as Honorary Consultant in Oral & Maxillofacial / Head and Neck Surgery at Aintree University Hospital and is a surgeon specializing in head and neck cancers at the University of Liverpool.
"Dr. Shaw is a Key Opinion Leader in head and neck cancer who has participated in numerous trials exploring better ways to treat cancer. We are honored to have his participation and expertise in our trial." stated CEL-SCI Chief Executive Officer Geert Kersten.
CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases.
((Comments on this story may be sent to firstname.lastname@example.org))
(c) 2015 ProQuest Information and Learning Company; All Rights Reserved., source Trade Publications